Sun Acquisitions

SEPTEMBER 16, 2024

Invest in strategic initiatives to boost your company’s performance and market position, ultimately increasing its valuation. Common exit strategies include selling to strategic buyers, private equity firms, management buyouts (MBOs), or going public through an initial public offering (IPO).

Negotiation 59

Negotiation Business Sale Management 59

Cooley M&A

MARCH 1, 2019

Even for a thriving business with a viable equity story, committed stakeholders and the right advisers, the final deal terms and valuation are typically guided by factors beyond a company’s control. Stock market forces also make the timing of an eventual outright exit and the final blended valuation of equity sales over time uncertain.

IPO 52

IPO Valuation M&A Business 52

Cooley M&A

JANUARY 23, 2024

For example, in the biopharma space, AbbVie, Bristol Myers Squibb, AstraZeneca, and Roche each announced multiple big-ticket acquisitions in the fourth quarter – including Abbvie’s acquisition of ImmunoGen for $10.1 billion; Bristol Myer Squibb’s acquisition of RayzeBio for $4.1 billion and Cerevel Therapeutics for $8.7

M&A 52

M&A Mergers and Acquisitions Acquisitions Pharmaceutical 52

Peak Frameworks

MAY 22, 2023

For example, Amazon's acquisition of Whole Foods in 2017 required careful analysis of the accounting equation to determine the financial impact of the transaction. Importance of Asset Valuation and Management Proper asset valuation and management are essential for businesses to maintain a healthy balance sheet and maximize their potential.

Accountant 52

Accountant Equities Debt Private Equity 52

Software Equity Group

MARCH 21, 2023

Minority investors aim to increase value and earn a return on their investment when your business undergoes additional transactions down the line, whether through additional capital raises, acquisition, or an initial public offering (IPO).

Finance 52

Finance Finance Debt Equities 52

Cooley M&A

MARCH 22, 2023

With the US initial public offering markets continuing to remain largely closed, and special purpose acquisition company combinations being costly and complex, there’s a new kid in town for foreign companies looking to go public in the US: reverse mergers.

Mergers 52

Mergers IT Mergers and Acquisitions IPO 52

Cooley M&A

JANUARY 25, 2023

Amid depressed valuations, biotechnology companies also saw an increasing number of demands from activist investors that in certain cases led to more deal activity. For example, the sale of Horizon Therapeutics to Amgen for approximately $28 billion was the third-largest all-cash transaction in the pharmaceutical sector in history.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Collaboration 40

Cooley M&A

JANUARY 30, 2024

These dynamics help explain why, despite significant sector-wide declines in public tech and life sciences company valuations from 2021 peaks, we have yet to mark a dramatic increase in activism campaigns relative to historical levels: for many would-be targets, there was no clear “fix” available.

Private Equity 52

Private Equity M&A Capital Investors 52

Cooley M&A

JANUARY 25, 2023

The year started off with a bang, with mega-deals such as Microsoft’s pending $69 billion acquisition of Activision Blizzard, Elon Musk’s $44 billion acquisition of Twitter and Broadcom’s pending $61 billion acquisition of VMware inked in quick succession. Tech M&A in 2022 was a tale of two halves. trillion. [2]

M&A 52

M&A Mergers and Acquisitions Private Equity Mergers 52

Focus Investment Banking

NOVEMBER 18, 2024

If you are not aware of the fundamental private equity model, it is simple: buy (or invest in) a company, grow profits through increasing sales, cutting costs and/or add-on acquisitions, and then sell the larger, more profitable company for significantly more than it was purchased for.

Private Equity 52

Private Equity Equities IPO Valuation 52

Cooley M&A

JANUARY 22, 2025

billion acquisition of Alpine Immune; by contrast, there were eight US biotech acquisitions exceeding $5 billion in 2023. 2024 saw companies focusing on internal research and development, innovative partnerships, and targeted bolt-on asset acquisitions to bolster their pipelines. from 2023. [1]

M&A 64

M&A Mergers and Acquisitions Pharmaceutical Acquisitions 64